Tuesday, November 10, 2026

@negligible_cap Oct 23 7 clicks

Negligible Capital on X

*INSTACART EXPLORING A SALE: INFORMATION Sale could value $CART at $16 - $17B and they've had preliminary talks with $DASH and $UBER

@ActAccordingly Oct 23 4 clicks

PAA Research on X

For those scoring at home, THREE c-suite executives have "retired" from their positions at $KNSL thus far this year (COO, CIO, and now the CFO). At a minimum this is a pretty glaring indictment of the company's growth prospects or it could signal something far more troubling. Either way, it raises a lot of questions for a company that has operated with a highly insular culture for a long time.

@convequity Oct 23 19 clicks

Convequity on X

Cerebras ($CBRS) is a taxi built for very fast inference while Nvidia ($NVDA) runs the bus network. Most of the confusion around CBRS comes from reviewing the wrong vehicle. In our view, Cerebras' wafer-scale design and abundant on-chip SRAM let it reach high utilization at batches of roughly 3–4. That makes it exceptionally fast for low-batch inference. GPUs need much larger batches and tightly connected clusters to get there, but their flexibility, scalability and throughput make them the better mass-market token factories. The bus wins on economics when serving many users at once. We think Cerebras is mostly attractive over the next two to three years, provided demand grows enough for premium-priced, high-speed inference rather than mostly low-cost, high-volume tokens. How big that premium segment gets is the main variable in our thesis.

@RagingVentures Oct 23 2 clicks

Raging Capital Ventures on X

$HAWK came public with MS and GS at the peak of the $PL and $SPCX space pump cycle. Investors likely bought the stock blindly without really understanding the business. Alas, the shareholder base is now transitioning into strong hands. I think those buyers will be rewarded.

@TheBenSchmark Oct 23

JabroniCoin.USD on X

BMO on $CENX: “Discussions centered on tariff uncertainty, Oklahoma smelter progress, current operations, improving free cash flow conversion & Hawesville monetization. Meanwhile, with CENX trading at 2.5x current spot-based EBITDA, valuation is compelling in our view.” 2.5X!

@convequity Oct 23 12 clicks

Convequity on X

$ORCL Spends More of Its Cash Flow on Capex Than $AMZN or $MSFT — Does the Backlog Justify the Stretch? We hold Oracle, so we pulled the numbers from our ABBX dashboard to check whether the contracted backlog supports the heavier spending. Capex intensity (last four quarters) Oracle spent about 161% of operating cash flow on capex (to 31 Aug 2026). Amazon was about 107% and Microsoft about 63% (both to 30 Jun 2026). Oracle put USD 75.7B into capex against USD 46.9B of operating cash flow. Debt and lease load Add borrowings, lease liabilities, and the undiscounted value of leases signed but not yet started. Purchase obligations are excluded for all three. - Oracle: about USD 457B, or 3.6x its USD 125B of borrowings. - Amazon: about 2.9x. - Microsoft: about 11x (its borrowings are small relative to lease commitments). Oracle stands out on size versus cash flow: roughly 9.7x trailing operating cash flow, versus 2.5x at Microsoft and 2.3x at Amazon. The backlog counterweight Oracle’s RPO (remaining performance obligations) is USD 664B — close to Microsoft’s USD 678B commercial RPO, while generating only about a quarter of Microsoft’s operating cash flow. RPO covers about 1.45x Oracle’s debt-plus-leases figure, versus 1.48x at Microsoft. Those contracts provide revenue visibility, though delivery still depends on margins and timing. Amazon’s USD 496B backlog is AWS-only, so it is not a clean comparison. ABBX capacity estimates show Oracle rising from about 4 GW to about 12.8 GW by 2029, Microsoft from 8.5 to 17 GW by 2030, and Amazon from 10.6 to 16 GW by 2028. That implies roughly USD 52B of RPO per planned GW for Oracle versus about USD 40B for Microsoft (rough scale comparison given different RPO scopes and time horizons). Our take The bigger risks at Oracle are timing, execution, and funding rather than a lack of demand. Oracle expects about 13% of its RPO to convert to revenue in the next 12 months while capex is being spent now. Its 12.8 GW figure is an ABBX estimate, not company guidance; it carries ABBX’s lowest confidence of the three, and grid approval is still pending at one or more sites. Oracle also sold USD 20B of stock in FQ1 FY27. We think the backlog justifies holding the position, but sized for funding risk. What we watch: RPO converting to revenue on schedule, new capacity coming online, and whether more equity is needed.

@StableBread Oct 23 4 clicks

Fajasy on X

Here’s where BWX Technologies’ $BWXT stock could be by the end of 2027, 15 months from now, in my bear, base, and bull cases. I value each case on 2028 adjusted EBITDA, since the market will be pricing 2028 numbers by then. For net debt, I use today’s $1.65B minus the $750M from its medical isotope sale, or $0.9B. To stay conservative, I don’t credit the FCF $BWXT earns between now and the end of 2027. Management plans to spend the cash, including on acquisitions, but hasn’t said how much or on what, so I leave out both the cash and any EBITDA acquisitions could potentially add. Therefore, each case’s value is 2028 adjusted EBITDA times the multiple, minus the $0.9B of net debt, over 92.0M diluted shares (its convertible notes only dilute above $262.51). Bear case ($118, -19%) The bear case assumes budgets slip (the government is running on a continuing resolution through December 11), the terms of its Janus contract (the Army’s microreactor program for military bases) disappoint, and new-build orders arrive later than John MacQuarrie, president of Commercial Operations, expects. That implies only 5%/year adjusted EBITDA growth to $735M in 2028, and a multiple of 16x, slightly below $BWXT’s 16.6x at the end of 2023, for a value of $118/share. Base case ($162, +11%, most likely) The base case assumes $BWXT delivers its 2027 framework (high-single-digit growth to $720M of adjusted EBITDA) and grows 10% in 2028 to $790M as new-build revenue starts. That implies the multiple holds at 20x, near today’s, for a value of $162/share. $BWXT’s own 2030 plan goes further. Today’s $15.0B EV is 13.0x the $1.15B midpoint of its 2030 adjusted EBITDA target. If $BWXT hits that midpoint, trades at 18x instead of the base case’s 20x, and runs at 2.5x net leverage (~$2.9B of net debt) after deploying its capital, the stock would be worth $194/share at the end of 2029. With ~$4/share of total dividends through 2029, that’s a 9.9%/year return from $145.70. But getting from the base case’s $790M in 2028 to $1.15B in 2030 takes ~21%/year growth, more than double the 2028 pace, so the new orders and acquisitions outside $BWXT’s predictable core (the programs backed by backlog and long-term contracts) have to show up. Bull case ($204, +40%) The bull case assumes a new-build order lands by early 2027, $BWXT signs a Janus contract on par with microreactor startup Radiant’s (up to $750M), and margins rise toward 20%. That implies adjusted EBITDA of $820M in 2028 and a re-rating to 24x, just under the 24.8x of Curtiss-Wright $CW today, for a value of $204/share. Notably, none of the three cases considers a commercial BANR (microreactor) sale, a Wyoming TRISO fuel plant, a battleship reactor, or a data center customer, so at $145.70/share, you’re getting commercial microreactors and data centers as a free option.